Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7016 and Temozolomide in BRAF wild-type melanoma
NCT01605162Phase 2Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2012
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of E7016 in melanoma, sponsored by Eisai Co., Ltd.. Started May 2012; status: terminated.
02
Drugs
E7016
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01605162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01605162.